



Entered

OIPE

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/10/040,128DATE: 04/17/2002  
TIME: 14:14:06Input Set : A:\seq.BK!  
Output Set: N:\CRF3\04172002\J040128.raw

4 <110> APPLICANT: Liao, Fang  
5 Hicklin, Daniel J.  
6 Bohlen, Peter  
W--> 7 <120> TITLE OF INVENTION: Antibody Antagonists of VE-Cadherin Without Adverse Effects  
on  
W--> 8 Vascular Permeability  
W--> 9 <130> FILE REFERENCE: 11245/46976  
W--> 10 <140> CURRENT APPLICATION NUMBER: filed 30 March 2001  
C--> 11 <141> CURRENT FILING DATE: 2001-03-30  
W--> 12 <160> NUMBER OF SEQ ID: 6  
13 <170> SOFTWARE: WordPerfect 8.0 for Windows  
15 <210> SEQ ID NO: 1  
16 <211> LENGTH: 15  
17 <212> TYPE: PRT  
18 <213> ORGANISM: Artificial Sequence  
W--> 19 <220> FEATURE:  
20 <223> OTHER INFORMATION: synthetic peptide  
W--> 21 <400> SEQUENCE: 1  
22 Asp Glu Ile Trp Asn Gln Met His Ile Asp Glu Glu Lys Asn Glu  
23 1 5 10 15  
25 <210> SEQ ID NO: 2  
26 <211> LENGTH: 15  
27 <212> TYPE: PRT  
28 <213> ORGANISM: Artificial Sequence  
W--> 29 <220> FEATURE:  
30 <223> OTHER INFORMATION: synthetic peptide  
W--> 31 <400> SEQUENCE: 2  
32 Asp Trp Ile Trp Asn Gln Met His Ile Asp Glu Glu Lys Asn Glu  
33 1 5 10 15  
35 <210> SEQ ID NO: 3  
36 <211> LENGTH: 15  
37 <212> TYPE: PRT  
38 <213> ORGANISM: Artificial Sequence  
W--> 39 <220> FEATURE:  
40 <223> OTHER INFORMATION: synthetic peptide  
W--> 41 <400> SEQUENCE: 3  
42 Asp Trp Ile Trp Asn Gln Met His Ile Asp Glu Glu Lys Asn Thr  
43 1 5 10 15  
45 <210> SEQ ID NO: 4  
46 <211> LENGTH: 16  
47 <212> TYPE: PRT  
48 <213> ORGANISM: Artificial Sequence  
W--> 49 <220> FEATURE:  
50 <223> OTHER INFORMATION: synthetic peptide

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/10/040,128

DATE: 04/17/2002  
TIME: 14:14:06

Input Set : A:\seq.BK!  
Output Set: N:\CRF3\04172002\J040128.raw

W--> 51 <400> SEQUENCE: 4  
52 Tyr Val Lys Asp Gln Ser Asn Tyr Asn Arg Gln Asn Ala Lys Tyr Cys  
53 1 5 10 15  
55 <210> SEQ ID NO: 5  
56 <211> LENGTH: 18  
57 <212> TYPE: PRT  
58 <213> ORGANISM: Artificial Sequence  
W--> 59 <220> FEATURE:  
60 <223> OTHER INFORMATION: synthetic peptide  
W--> 61 <400> SEQUENCE: 5  
62 Lys Tyr Val Leu Gln Gly Glu Phe Ala Gly Lys Ile Phe Gly Val Asp  
63 1 5 10 15  
65 Ala Cys  
66 18  
68 <210> SEQ ID NO: 6  
69 <211> LENGTH: 15  
70 <212> TYPE: PRT  
71 <213> ORGANISM: Artificial Sequence  
W--> 72 <220> FEATURE:  
73 <223> OTHER INFORMATION: synthetic peptide  
W--> 74 <400> SEQUENCE: 6  
75 Leu Ile Val Asp Lys Asn Thr Asn Lys Asn Leu Glu Gln Pro Cys  
76 1 5 10 15

## VERIFICATION SUMMARY

PATENT APPLICATION: US/10/040,128

DATE: 04/17/2002

TIME: 14:14:07

Input Set : A:\seq.BK!

Output Set: N:\CRF3\04172002\J040128.raw

L:7 M:283 W: Missing Blank Line separator, <120> field identifier  
L:9 M:283 W: Missing Blank Line separator, <130> field identifier  
L:10 M:283 W: Missing Blank Line separator, <140> field identifier  
L:10 M:270 C: Current Application Number differs, Replaced Current Application Number  
L:11 M:271 C: Current Filing Date differs, Replaced Current Filing Date  
L:12 M:283 W: Missing Blank Line separator, <160> field identifier  
L:19 M:283 W: Missing Blank Line separator, <220> field identifier  
L:21 M:283 W: Missing Blank Line separator, <400> field identifier  
L:29 M:283 W: Missing Blank Line separator, <220> field identifier  
L:31 M:283 W: Missing Blank Line separator, <400> field identifier  
L:39 M:283 W: Missing Blank Line separator, <220> field identifier  
L:41 M:283 W: Missing Blank Line separator, <400> field identifier  
L:49 M:283 W: Missing Blank Line separator, <220> field identifier  
L:51 M:283 W: Missing Blank Line separator, <400> field identifier  
L:59 M:283 W: Missing Blank Line separator, <220> field identifier  
L:61 M:283 W: Missing Blank Line separator, <400> field identifier  
L:72 M:283 W: Missing Blank Line separator, <220> field identifier  
L:74 M:283 W: Missing Blank Line separator, <400> field identifier